Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | PARG | Q86W56 | 13/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2816820 | 0.79 | TBXA2R (0.47) | HRH1HTR6 | |
| SCHEMBL2811870 | 0.78 | HDAC6 (0.41) | HRH1HTR6 | |
| SCHEMBL2814605 | 0.78 | SCN9A (0.38) | PARGPTGDR2HRH1HTR6 | |
| SCHEMBL2812789 | 0.78 | HRH1 (0.48) | HRH1HTR6 | |
| SCHEMBL951917 | 0.77 | MCHR1 (0.38) | HRH1HTR6 | |
| SCHEMBL2810391 | 0.76 | TBXA2R (0.55) | HRH1HTR6 | |
| SCHEMBL957244 | 0.76 | CYP17A1 (0.44) | GRIN1GRIN2BHRH1HTR6 | |
| SCHEMBL2812940 | 0.75 | TBXA2R (0.45) | HRH1HTR6 | |
| SCHEMBL2810996 | 0.75 | HRH1 (0.51) | GRIN1GRIN2BPTGDR2HRH1HTR6 | |
| SCHEMBL960009 | 0.75 | TBXA2R (0.40) | HRH1HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9983218-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2018-05-29 | — | — | US | claimed |
| US-20180024144-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC. (US) | 2018-01-25 | — | — | US | claimed |
| US-20100249105-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | US | claimed |
| US-9983218-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20180024144-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-9625475-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20100249105-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249105-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | GRIN1 1088/4885GRIN2B 1145/4885PARG 2927/4885 |
| US-20180024144-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | GRIN1 1088/4885GRIN2B 1145/4885PARG 2927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.